We found that the knockdown of CBP decreased the expression of cyclinD1 which was one of the downstream molecules of β-catenin/CBP, but concomitantly increased the expression level of JUN which was a downstream molecule of β-catenin/p300, independent of the mutation status of BCR-ABL in CML cells (Figure 3A). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.